Regenexx, LLC
16
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
43.8%
7 terminated/withdrawn out of 16 trials
46.2%
-40.4% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Platelet Lysate vs Saline for Lumbosacral Radiculopathy
Role: lead
Trial for Treating Painful Degenerative Disc Disease
Role: lead
A Clinical Registry of Orthobiologics Procedures
Role: lead
Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries
Role: lead
Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study
Role: lead
Randomized Trial of Regenexx Stem Cell Support Formula
Role: lead
Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears
Role: lead
Regenexx™ SD Versus Exercise Therapy for ACL Tears
Role: lead
Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment
Role: lead
A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain
Role: lead
Nebulized PL for Post-COVID-19 Syndrome
Role: lead
Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage
Role: lead
Case Series on Using Bone Marrow Concentrate for Alar Ligament Injuries
Role: lead
Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA
Role: lead
A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment
Role: lead
Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy
Role: lead
All 16 trials loaded